A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease

Trial Profile

A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Nilvadipine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms NILVAD
  • Most Recent Events

    • 20 Jul 2017 Trial design and study execution details, presented at the Alzheimer's Association International Conference 2017.
    • 11 Jan 2017 Status changed to completed.
    • 26 May 2015 Planned primary completion date changed from 1 May 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top